PharmAbcine Inc
208340
Company Profile
Business description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Contact
70, 2, 2nd Floor, KT Daedeok 2 Research Center
Jeonmin-dong
Yuseong-dong
Daejeon Metropolitan City1689
KORT: +82 428632017
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
40
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,206.07 | 31.87 | 0.39% |
| DAX 40 | 24,258.80 | 427.81 | 1.80% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,403.57 | 49.00 | 0.52% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,317.40 | 27.56 | -0.21% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |